Antares Pharma Cmn (ATRS) 1.06 $ATRS Antares Pharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antares Pharma Cmn (ATRS) 1.06 $ATRS

Antares Pharma (ATRS) in Focus: Stock Moves 10.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:05AM CDT
Antares Pharma Inc. (ATRS) was a big mover last session, as the company saw its shares rise more than 10% on the day.
HYH: 34.23 (-0.24), ATRS: 1.06 (+0.03)

What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 32.18 (+0.07), GMED: 24.96 (+0.09), NUVA: 62.31 (+1.49), ATRS: 1.06 (+0.03)

Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product
GlobeNewswire - Thu Jun 23, 9:54AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva's ANDA No. 205984 in the United States.
ATRS: 1.06 (+0.03)

Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Tue Jun 21, 8:02AM CDT
LONDON, June 21, 2016 /PRNewswire/ --
ATRS: 1.06 (+0.03)

Antares Pharma to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 p.m. Eastern Time.
ATRS: 1.06 (+0.03)

Antares Pharma Announces Update to QuickShot Testosterone Clinical Program
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic phase 3 study of QuickShot(R) Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005 included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. The study was conducted to help ensure that we satisfy the U.S. Food and Drug Administration's recommendation that we have a safety database of approximately 350 subjects exposed to QS T in total with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year.
ATRS: 1.06 (+0.03)

Antares Pharma reports 1Q loss
Automated Insights - Mon May 09, 6:08AM CDT
EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Monday reported a loss of $7.7 million in its first quarter.
ATRS: 1.06 (+0.03)

Antares Pharma To Host First Quarter Operating And Financial Results Conference Call
GlobeNewswire - Mon May 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its first quarter 2016 financial results and recent operating progress before the market opens on Monday, May 9, 2016, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Robert F. Apple, President and Chief Executive Officer will host the call.
ATRS: 1.06 (+0.03)

New Strong Sell Stocks for April 28th
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
CAVM: 40.74 (+1.19), CMG: 405.60 (+5.89), SAM: 171.03 (-0.10), DOV: 71.17 (+0.83), ATRS: 1.06 (+0.03)

Antares Pharma to Present at the Deutsche Bank Securities, Inc. 41st Annual Health Care Conference
GlobeNewswire - Wed Apr 27, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 41 Annual Health Care Conference on Wednesday May 4, 2016 at 9:20 am Eastern Time.
DB: 13.28 (+0.31), ATRS: 1.06 (+0.03)

OTREXUP.COM Website Awarded a Bronze Horizon Interactive Award
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the Company's OTREXUP.COM website has been awarded a 2015 Bronze Horizon Interactive Award in the category of Consumer Information Websites. The Horizon Interactive Awards are among the most prestigious awards in the field of interactive and creative media. The annual international competition, now in its 14 season, recognizes, promotes and awards the best web sites, videos, online advertising, print media and mobile applications. In 2015 alone, Horizon received over 1,100 competition submissions from more than 40 countries. A volunteer panel of industry professionals review the entries to determine the recognition and shed a spotlight on the winners and the people who made it happen.
ATRS: 1.06 (+0.03)

4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 2.49 (+0.01), SUNE: 0.34 (unch), ATRS: 1.06 (+0.03)

Antares Pharma Discloses "Pen 1" Development Project as Teriparatide
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today disclosed that the "Pen 1" development project with Teva Pharmaceutical Industries, Ltd. (Teva) relates to a generic form of Forteo (teriparatide [rDNA origin] injection) (Teriparatide), marketed by Eli Lilly and Company (Lilly). Forteo is an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal women. On March 16, 2016 Lilly filed a lawsuit against Teva in response to Teva's Paragraph IV notice and filing contained in their Abbreviated New Drug Application (ANDA) for Teriparatide filed with, and accepted by, the U.S. Food and Drug Administration (FDA). Based on available information, Antares believes that Teva may be the "first applicant" to file an ANDA for a generic equivalent of Forteo and, should Teva's ANDA be approved, may be entitled to 180 days of generic market exclusivity.
ATRS: 1.06 (+0.03)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 55.27 (+0.51), ALIM: 1.30 (+0.02), AMD: 5.13 (+0.03), CWT: 33.94 (-0.16), ATRS: 1.06 (+0.03)

New Strong Sell Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:07AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRME: 5.36 (-0.10), ACAS: 15.90 (+0.04), ATTU: 10.10 (+0.11), CWT: 33.94 (-0.16), ATRS: 1.06 (+0.03)

Additional Dosage Strengths of Otrexup(TM) (methotrexate) Injection Approved by FDA
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval by the U.S. Food and Drug Administration (FDA) of three new dosage strengths of OTREXUP (methotrexate) injection. The new dosage strengths of 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml will complement the already approved and marketed strengths of 7.5 mg/0.4 ml, 10 mg/0.4 ml, 15 mg/0.4 ml, 20 mg/0.4 ml, and 25 mg/0.4 ml. New, interim dose-strength options will enable physicians to select more specific, optimal doses to help achieve patient treatment goals.
ATRS: 1.06 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles